Floyd E - Search Results

1

Commentary: a view on discovery pathology.

Burkhardt JE, Floyd E, Kerlin RL, Adler RR, Ochoa R, Reynolds JA. Burkhardt JE, et al. Among authors: floyd e. Toxicol Pathol. 1999 Jul-Aug;27(4):472-3. doi: 10.1177/019262339902700414. Toxicol Pathol. 1999. PMID: 10485831 No abstract available.

2

The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.

Floyd E, Mann P, Long G, Ochoa R. Floyd E, et al. Toxicol Pathol. 2002 Jan-Feb;30(1):147-56. doi: 10.1080/01926230252824860. Toxicol Pathol. 2002. PMID: 11890468 Review.

3

Development and use of biomarkers in oncology drug development.

Floyd E, McShane TM. Floyd E, et al. Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:106-15. doi: 10.1080/01926230490425021. Toxicol Pathol. 2004. PMID: 15209410 Review.

4

Acute drug-induced vascular injury in beagle dogs: pathology and correlating genomic expression.

Enerson BE, Lin A, Lu B, Zhao H, Lawton MP, Floyd E. Enerson BE, et al. Among authors: floyd e. Toxicol Pathol. 2006;34(1):27-32. doi: 10.1080/01926230500512068. Toxicol Pathol. 2006. PMID: 16507541

5

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.

Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK. Jani JP, et al. Among authors: floyd e. Cancer Res. 2007 Oct 15;67(20):9887-93. doi: 10.1158/0008-5472.CAN-06-3559. Cancer Res. 2007. PMID: 17942920

6

Pathway analysis using random forests classification and regression.

Pang H, Lin A, Holford M, Enerson BE, Lu B, Lawton MP, Floyd E, Zhao H. Pang H, et al. Among authors: floyd e. Bioinformatics. 2006 Aug 15;22(16):2028-36. doi: 10.1093/bioinformatics/btl344. Epub 2006 Jun 29. Bioinformatics. 2006. PMID: 16809386

7

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG. Beebe JS, et al. Among authors: floyd e. Cancer Res. 2003 Nov 1;63(21):7301-9. Cancer Res. 2003. PMID: 14612527

8

The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma.

Paradis TJ, Floyd E, Burkwit J, Cole SH, Brunson B, Elliott E, Gilman S, Gladue RP. Paradis TJ, et al. Among authors: floyd e. Cancer Immunol Immunother. 2001 May;50(3):125-33. doi: 10.1007/s002620100181. Cancer Immunol Immunother. 2001. PMID: 11419179 Free PMC article.

9

A Survey of Employed Orthopedic Surgeons Ability to Estimate Operating Room Device Costs.

Derby M, Floyd E, Sturdevant D, O'Connor H, Skelley N. Derby M, et al. Among authors: floyd e. S D Med. 2024 Dec;77(12):534-539. S D Med. 2024. PMID: 39841793

10

Desorption efficiency and holding capacity of acid-treated filters for nicotine sampling in vape shops.

Oni TM, Gamagedara S, Floyd EL. Oni TM, et al. Among authors: floyd el. Ann Work Expo Health. 2025 Jan 8;69(1):104-108. doi: 10.1093/annweh/wxae080. Ann Work Expo Health. 2025. PMID: 39450758 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters